AbbVie Inc. (ABBV)
| Market Cap | 401.47B +25.0% |
| Revenue (ttm) | 62.82B +9.5% |
| Net Income | 3.60B -13.3% |
| EPS | 2.03 -13.2% |
| Shares Out | 1.77B |
| PE Ratio | 111.93 |
| Forward PE | 15.26 |
| Dividend | $6.92 (3.05%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 6,248,114 |
| Open | 227.37 |
| Previous Close | 224.94 |
| Day's Range | 226.00 - 230.47 |
| 52-Week Range | 181.73 - 244.81 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 253.55 (+11.58%) |
| Earnings Date | Apr 29, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 32 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $253.55, which is an increase of 11.58% from the latest price.
News
AbbVie announces EC authorizes expanded label for Venclyxto
AbbVie (ABBV) announced that the European Commission has authorized an expanded label for Venclyxto to include use in combination with acalabrutinib and use in combination with ibrutinib for the treat...
FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm
The Food and Drug Administration approved pivekimab sunirine-pvzy, or Decnupaz, from AbbVie (ABBV), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendr...
AbbVie reports positive CHMP opinion for Maviret
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Maviret, an oral pangenotypic direct...
AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey
Allergan Aesthetics, an AbbVie (ABBV) company, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of Boe...
AbbVie price target lowered to $235 from $236 at Evercore ISI
Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $235 from $236 and keeps an Outperform rating on the shares.
3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
The article uses TipRanks’ Dividend Aristocrat tool to identify AbbVie ($ABBV), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) as three dividend aristocrat stocks with a Strong Buy rating on Wa...
AbbVie price target raised to $298 from $294 at Piper Sandler
Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $298 from $294 and keeps an Overweight rating on the shares. The depth of AbbVie’s inflammatory bowel disease pipeline…
AbbVie Transcript: Bank of America Global Healthcare Conference 2026
Management projects strong revenue and margin growth through 2031, driven by core products, diversified pipeline, and strategic M&A. Key innovations include new obesity assets, combination therapies in IBD, and advances in CAR T and psychedelics.
AbbVie Transcript: AGM 2026
Record revenues and strong sales growth fueled increased R&D and strategic investments. Shareholders approved director elections, auditor ratification, and executive compensation, but rejected proposals to eliminate supermajority voting and require an independent board chair.
AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW
AbbVie (ABBV) announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week, or DDW, Annual Meeting, May 2-5 in Chicago. AbbVie will present 18…
AbbVie price target raised to $236 from $232 at Evercore ISI
Evercore ISI raised the firm’s price target on AbbVie (ABBV) to $236 from $232 and keeps an Outperform rating on the shares.
AbbVie price target raised to $278 from $270 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $278 from $270 and keeps an Overweight rating on the shares. The company reported a solid quarter from the…
AbbVie price target raised to $265 from $262 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $265 from $262 and keeps a Buy rating on the shares. The firm said ABBV delivered upside…
AbbVie upgraded to Buy at BofA on durable growth
As previously reported, BofA analyst Tim Anderson upgraded AbbVie (ABBV) to Buy from Neutral with a price target of $234, up from $226. The firm believes concerns around competitive erosion…
AbbVie upgraded to Buy from Neutral at BofA
BofA upgraded AbbVie (ABBV) to Buy from Neutral with a price target of $234, up from $226.